PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Rokit Healthcare posted steady quarterly revenue growth and turned operating-profit positive for full-year 2025, but 2026 has seen operating and net losses widen again as clinical and US expansion costs ramp up.
2025 consolidated revenue reached KRW 26.247 billion (roughly double the prior year), with annual operating profit of KRW 453 million marking the first full-year operating profit since listing.
However, operating losses returned in both 2026 Q1 (-KRW 2.351 billion) and Q2 (-KRW 13.453 billion), with the Q2 net loss attributable to owners widening to KRW 9.341 billion.
Expansion into cartilage, kidney, and skin-cancer indications, along with rising costs at its US subsidiary, were cited as key drivers of the widened losses in H1 2026.
Owners' equity turned positive at KRW 11.559 billion in 2025, ending years of complete capital impairment.
Pipeline expansion continues via a kidney-regeneration collaboration with Harvard Medical School researchers and multi-country patents, though clinical and commercialization timelines remain uncertain.
Rokit Healthcare has commercialized an organ-regeneration platform that combines AI-based wound modeling, a medical 3D bioprinter, personalized bioink, and disposable regeneration kits.
Revenue is broadly split between equipment sales (3D bioprinters) and consumables repeatedly used per patient, such as bioink and fat-processing kits, which the company says carry a gross margin of roughly 80%.
Its core product is a platform that uses a patient's own fat tissue to regenerate skin for diabetic foot ulcer patients, already generating sales in markets including the United States and parts of Latin America.
The company has also launched AI-FRESH, an autologous blood-based regenerative treatment service, while running multi-country clinical work to expand into cartilage, kidney, skin cancer, and burn indications.
It pursues platform sales agreements with partners across many countries, and in the US has supplied its skin and diabetic foot regeneration platform to institutions including Veterans Health Administration hospitals and Northwell Health.
Subsidiaries include ROKIT America, which runs an NMN dietary-supplement business, and ROKIT Genomics, which handles single-cell RNA genetic data. In Korea's 3D bioprinting and regenerative medicine space, companies such as Graphy, T&R Biofab, and L&C Bio operate in adjacent or competing areas.
While equipment and consumable sales remain the core today, the business model carries potential to expand toward treatment-service and licensing revenue over the longer term.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩6B | ₩21,533,779 | 0.4% |
| 2025Q3 | ₩7B | ₩77,538,648 | 1.1% |
| 2025Q4 | ₩9.6B | ₩600M | 6.3% |
| 2026Q1 | ₩8.1B | -₩2.4B | −29.2% |
| 2026Q2 | ₩8.2B | -₩13.5B | −163.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩9.2B | -₩13.9B | ₩1.9B | −151.7% | — | −114.5% |
| 2023 | ₩12.4B | -₩7.4B | ₩16.6B | −59.4% | — | −110.8% |
| 2024 | ₩13.1B | -₩5.6B | -₩7.6B | −42.5% | — | −114.7% |
| 2025 | ₩26.2B | ₩500M | -₩2.8B | 1.7% | −24.6% | 376.3% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
Rokit Healthcare's annual revenue rose steadily from KRW 9.151 billion in 2022 to KRW 12.418 billion in 2023, KRW 13.111 billion in 2024, and KRW 26.247 billion in 2025, with revenue roughly doubling year-on-year in 2025.
Operating losses persisted at -KRW 13.878 billion in 2022, -KRW 7.378 billion in 2023, and -KRW 5.572 billion in 2024, before the company posted its first full-year operating profit of KRW 453 million in 2025 (a 1.7% operating margin).
Net income told a different story: net income attributable to owners was a profit of KRW 1.875 billion in 2022 and a large KRW 16.600 billion in 2023, before swinging to a loss of -KRW 7.646 billion in 2024 and remaining a loss of -KRW 2.845 billion in 2025.
Quarterly operating profit turned positive starting in Q2 2025, improving from KRW 22 million in Q2 to KRW 78 million in Q3 and KRW 600 million in Q4, but reversed sharply into losses of -KRW 2.351 billion in Q1 2026 and -KRW 13.453 billion in Q2 2026.
Net losses attributable to owners also widened, from -KRW 972 million, -KRW 1.160 billion, and -KRW 355 million in Q2 through Q4 2025 to -KRW 1.834 billion in Q1 2026 and -KRW 9.341 billion in Q2 2026, bringing the cumulative net loss attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) to KRW 12.690 billion.
Operating cash flow, which ran between roughly -KRW 4.0 billion and -KRW 6.6 billion annually from 2022 to 2024, deteriorated further to -KRW 17.230 billion in 2025.
On the balance sheet, owners' equity was deeply negative at -KRW 97.456 billion, -KRW 78.457 billion, and -KRW 77.073 billion in 2022 through 2024 respectively, reflecting complete capital impairment, before turning positive at KRW 11.559 billion in 2025, with the debt ratio easing to 376.3%.
The company has attributed the wider H1 2026 losses mainly to a sharp increase in R&D spending tied to cartilage and kidney regeneration clinical work, along with rising marketing and professional-service costs at its US subsidiary.
The medical 3D bioprinting and regenerative medicine industry is in an early growth phase, targeting conditions with few treatment alternatives amid rising chronic disease prevalence such as diabetes and chronic kidney disease, combined with an aging population.
In Korea, regulatory approvals for new-indication clinical research continue under the advanced regenerative medicine framework, with companies such as Graphy, T&R Biofab, and L&C Bio operating in competing or adjacent segments of 3D bioprinting and tissue regeneration alongside Rokit Healthcare.
Industry sources have indicated that certain indication markets, such as skin-cancer regeneration treatment, are expected to grow to more than $900 million by 2030.
Rokit Healthcare claims a first-mover technological edge, citing its commercialization of what it describes as the world's first medical 3D bioprinter and automated wound-modeling AI, and has progressed to the point of securing a US CPT reimbursement code for diabetic foot ulcer treatment that allows insurance billing.
That said, the competitive landscape could shift if larger global medical device or pharmaceutical companies enter similar spaces, and differing reimbursement and approval processes across countries create uneven commercialization speed by region.
Overall industry growth appears likely, but whether capital-constrained, smaller technology-listed companies in Korea can keep pace with better-capitalized rivals on clinical and regulatory timelines remains a key question.
In its original IPO prospectus, the company targeted revenue of KRW 23.8 billion in 2025, KRW 41.4 billion in 2026, and KRW 65.5 billion in 2027, and actual 2025 revenue of KRW 26.247 billion came in above that initial target.
In a March 2026 report, IBK Securities projected that revenue growth would continue into 2026, while also expecting operating profit volatility to increase as kidney and cartilage regeneration clinical work ramped up related costs — a pattern that materialized in the H1 2026 results.
On the pipeline front, the company reported that its AI omentum-based kidney regeneration patch, evaluated in a collaborative preclinical study with Dr.
Joseph Bonventre's team at Harvard Medical School's Brigham and Women's Hospital, preserved kidney function (glomerular filtration rate) by roughly 62.5% in an animal model, and said it plans to pursue a domestic pilot clinical trial in patients with stage 3-4 chronic kidney disease in the second half of 2026, followed by broader clinical trials centered on Korea and the United States.
Core kidney-regeneration technology has already secured patents in Korea, Japan, and the United States.
On financing, the company raised approximately KRW 62.5 billion through a third-party placement of redeemable convertible preferred shares in March 2026, reportedly from global private equity and asset management investors, to fund R&D and clinical activities; however, these shares are subject to a one-year lock-up, after which additional tradable supply could emerge.
On balance, revenue growth momentum appears intact, but the company is in a phase where multiple new indications entering clinical stages simultaneously are driving up both cost burden and earnings volatility.
Because Rokit Healthcare continues to post net losses, conventional price-to-earnings-based valuation comparisons are difficult to apply at this stage.
Its price-to-book ratio reflects a very small and still-volatile net asset base, given that owners' equity only recently turned positive in 2025 after years of complete capital impairment, placing the premium over book value above typical sector averages.
The company pays no dividend, so dividend-yield comparisons with income-oriented peers in the sector are not meaningful.
Looking at the multi-year earnings pattern, operating results swung from losses to a single year of profit in 2025 before reverting to losses in 2026, while net income has shown large swings driven by non-operating items such as convertible-bond fair-value changes on a quarterly basis.
Given this earnings non-linearity and the pace of capital-structure change, market valuation appears to rely more heavily on expectations for future revenue growth and the speed of earnings stabilization than on current book value or past profit and loss.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
After equipment sales, bioink and disposable kit consumables are used repeatedly per patient, and the company has stated that consumable gross margins run around 80%. This structure could create a leverage effect where expanding equipment placement drives a parallel rise in follow-on consumable sales.
As commercialization across dozens of countries expands, the absolute scale of this recurring revenue has room to grow.
Beyond diabetic foot ulcer treatment, the company is expanding into cartilage, kidney, skin cancer, and burn indications, and has reported that a kidney regeneration collaboration with Dr.
Joseph Bonventre's team at Harvard Medical School's Brigham and Women's Hospital confirmed kidney function preservation in an animal model. Collaboration with a reputable overseas research institution could strengthen clinical evidence and credibility during future regulatory review. Core kidney regeneration technology has already secured patents in Korea, Japan, and the United States.
Owners' equity, which showed complete capital impairment every year from 2022 to 2024, turned positive at KRW 11.559 billion in 2025, with the debt ratio easing to 376.3%.
In March 2026, the company secured roughly KRW 62.5 billion through a third-party placement of redeemable convertible preferred shares to fund further R&D and clinical work. Continued capital raises have gradually eased the financial fragility seen in prior years.
Operating profit, which had improved quarter over quarter through 2025, reversed into sizable losses of -KRW 2.351 billion in Q1 2026 and -KRW 13.453 billion in Q2 2026.
A sharp rise in R&D spending tied to cartilage and kidney regeneration clinical work, along with increased costs at the US subsidiary, have been cited as the main drivers, illustrating how cost burden can grow alongside new indications. If cost growth outpaces revenue growth, the timeline for earnings stabilization could be pushed further out.
Net losses attributable to owners totaled KRW 12.690 billion over the most recent four quarters (Q3 2025 through Q2 2026), with Q2 2026 alone posting a loss of -KRW 9.341 billion.
Net income is heavily influenced by non-operating valuation items such as convertible bonds, causing large quarter-to-quarter swings that make it difficult to judge performance from operating profit alone. Operating cash flow also deteriorated to -KRW 17.230 billion in 2025, a larger outflow than in prior years.
The company has funded itself through convertible bonds and redeemable convertible preferred shares, and both the conversion of remaining convertible bonds and the lock-up expiry (roughly one year out) of the RCPS issued in March 2026 remain potential sources of increased share count going forward.
Continued dilution could increase volatility in per-share metrics, and large supply releases could create near-term supply-demand pressure.
The debt ratio remains elevated at 376.3%, and given years of complete capital impairment in the past, any need for further funding could again rely on dilutive instruments such as convertible bonds or preferred shares. Persistently negative operating cash flow also heightens dependence on external financing.
New indications such as kidney and cartilage regeneration must move beyond preclinical stages through human clinical trials and country-specific approval and reimbursement processes before commercialization.
Regulatory pathways and timelines differ by country, and the possibility of delays or clinical results falling short of expectations cannot be ruled out.
Competitive intensity could rise not only from domestic peers such as Graphy, T&R Biofab, and L&C Bio, but also if larger, better-capitalized overseas medical device or pharmaceutical companies enter the regenerative medicine market.
In addition, policy changes or adjustments to public insurance coverage in specific countries could affect the pace of revenue growth.
Watch whether Q3 2026 revenue growth continues and whether the R&D and US business costs that spiked in Q2 begin to stabilize.
Confirm whether the domestic pilot clinical trial for stage 3-4 chronic kidney disease patients begins, and monitor early progress.
Check whether the company proceeds with a US FDA Expanded Access Program (EAP) application using data from its Harvard Medical School collaboration.
Track the progress of remaining convertible bond conversions and changes in total shares outstanding to monitor dilution trends.
This marks the one-year lock-up expiry for the RCPS issued in March 2026; watch for supply-demand effects from the resulting increase in tradable shares.
Rokit Healthcare's 2025 full-year revenue doubled year-on-year and the company posted its first full-year operating profit, signaling progress toward commercialization, but in 2026 operating and net losses widened again as cartilage and kidney regeneration clinical work ramped up alongside rising US business costs.
Revenue growth itself has continued fairly steadily across quarters, and clinical evidence-building activities, including the Harvard Medical School collaboration, have continued as well.
At the same time, owners' equity turned positive for the first time in 2025, ending years of complete capital impairment, though the funding structure built on convertible bonds and redeemable convertible preferred shares remains a potential source of future dilution.
Ultimately, the company's investment narrative sits at a point where bullish factors—revenue growth and pipeline expansion—and bearish factors—earnings volatility and dilution concerns—are both actively in play.
The upcoming Q3 earnings release and progress on the kidney regeneration clinical trial are likely to offer important clues on the pace of future earnings stabilization. This report is intended for informational purposes only and does not constitute a buy or sell recommendation.
Report written 2026-10-02 · Data as of 2026-10-01
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.